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Magnetic resonance imaging (MRI) has an established role in imaging pelvic gynaecological malignancies. It is routinely
used in staging endometrial and cervical cancer, characterizing adnexal masses, selecting optimal treatment,
monitoring treatment and detecting recurrent disease. MRI has also been shown to have an excellent performance and
an evolving role in surveillance of patients after chemoradiotherapy in cervical cancer, post-trachelectomy, detecting
early recurrence and planning exenterative surgery in isolated central recurrences in both cervical and endometrial
cancer and in young patients on surveillance for medically managed endometrial cancer. However, conventional MRI
still has limitations when the morphological appearance of early recurrent or residual disease overlaps with normal
pelvic anatomy or treatment effects in the pelvis. In particular, after chemoradiotherapy for cervical cancer, distinguishing
between radiotherapy changes and residual or early recurrent disease within the cervix or the vaginal vault can be
challenging on conventional MRI alone. Therefore, there is an emerging need for functional imaging to overcome these
limitations. The purpose of this paper is to discuss the emerging functional MRI techniques and their applications in
predicting treatment response, detecting residual disease and early recurrent disease to optimize the treatment options
available using diffusion-weighted imaging and dynamic contrast enhancement particularly in cervical and endometrial
cancer.
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MRI has a pivotal and established role in detection and
staging of gynaecological malignancy. The exquisite soft
tissue resolution of MRI allows accurate demonstration of
tumour size, location, extension and nodal involvement.
Despite excellent clinical utilisation to date, conventional
T1 and T2 sequences cannot provide information about
tumour microenvironment and have limitations in asses-
sing response of tumours to therapy and in particular,
differentiating residual or recurrent disease from post-
treatment fibrosis due to overlap of morphological appear-
ances [1]. This latter distinction is crucial in selecting
patients who may benefit from further salvage treatment
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article, unless otherwise stated.Functional MRI has evolved over recent years with the
development of stronger field strengths, receiver coils and
pulse sequences and has proven benefit in cerebral, breast
and rectal cancers [2]. The clinical utilisation of functional
MRI in gynaecological malignancy is not yet established.
There is however an emerging body of evidence to sup-
port its use in the assessment of tumour response to ther-
apy with promising results to date, particularly in cervical
cancer.
As we learn more about tumour heterogeneity and de-
velop sophisticated therapeutic options, the need for an
imaging biomarker is essential to improve patient care and
ultimately long-term survival.Review
Clinical need for functional imaging techniques
Cervical cancer is the leading gynaecological cancer world-
wide and a significant proportion of patients will developioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Organ confined FIGO stage 1a/Ib disease is treated surgi-
cally and locally advanced disease is treated by chemoradia-
tion. Imaging within three months of therapy is particularly
challenging to interpret following radiotherapy as the
tumour microenvironment is affected by hypoxia, granula-
tion tissue and oedema and both residual disease and radi-
ation fibrosis show increased T2 signal intensity [4] (see
Figures 1 and 2). In this setting MRI is limited by false
positive results, as demonstrated by Vincens et al, who cor-
related end of treatment MRI results with histopathological
findings in patients with cervical cancer and found a
sensitivity and specificity of 80% and 55% respectively
for the detection of residual disease [5]. Developing an
imaging biomarker that can pre-empt poor response to
radiotherapy and detect residual disease and early re-
currence with good accuracy would have profound
prognostic implications.
The standard of care in early endometrial carcinoma is
surgery with good outcomes owing to the early stage of
presentation (80% of endometrial cancers are stage 1)
[6]. However its incidence continues to rise with a 40%
increase in the UK since 1993 [7]. The overall risk of re-
currence is published at 13% and commonly occurs at
the vaginal vault and pelvic lymph nodes but as there is
a lack of consensus over optimal surveillance methods
and patients may be asymptomatic, detection of recur-
rence can be challenging [8]. A reproducible biomarker
to select those patients at risk of recurrence would simi-
larly have great clinical impact.
Following endometrial cancer, ovarian cancer is the sec-
ond most common gynaecological malignancy associatedFigure 1 Residual or recurrent disease and post treatment complete
intensity mass in the cervix which is either residual or recurrent disease (a)
high signal on b1200 image (b) and low signal on the corresponding ADC
disease on T2 weighted sagittal images and axial DWI images.with high mortality rates due to late presentation [9]. Stage
III disease is associated with a 5 year survival of 32-47%
and following chemotherapy, relapse rates are high with a
median progression free survival of 18 months [10]. 18 F-
FDG PET/CT is the mainstay of imaging patients with
suspected recurrence and performs better than CT and
MRI and is particularly useful in detecting patients with
irresectable disease [11]. MRI and CT perform less well
than in primary staging due to the microscopic nature of
peritoneal seeding and distortion of anatomy in the post-
surgical state [12].
Results from the MRC OV05/EORTC 55955 trial con-
cluded a lack of survival benefit in asymptomatic pa-
tients with biochemical relapse [13], however it remains
important to develop imaging techniques to enable se-
lection of symptomatic patients with early recurrence
who may benefit from secondary cytoreduction which is
associated with an increase in median survival [14].
Functional imaging techniques
Changes in tumour microenvironment at a molecular
level are known to precede morphological changes dem-
onstrated on conventional MRI [15]. Dynamic contrast
enhanced (DCE) MRI and diffusion weighted imaging
(DWI) sequences reflect changes in oxygenation, perfu-
sion and tissue physiology of the tumour microstructure
and yield quantitative and semi-quantitative parameters
which can potentially be used as a biomarker of tumour
characteristics [2,16,17].
The ability to predict which cancers may respond to
primary treatment provides an opportunity to manipu-
late treatment pathways. This allows the clinicians toresponse. Sagittal T2 image demonstrating an intermediate T2 signal
, axial DWI images through the tumour showing restricted diffusion,
map (c). Post-treatment images (d-f) demonstrating no residual
Figure 2 Residual cervical disease. Post treatment images showing a small area of residual disease in the anterior lip of the cervix on sagittal
T2 MRI (a) and corresponding restricted diffusion (b and c).
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treatment regimes with toxic side effects and high costs,
whilst allowing other more suitable options to be insti-
tuted earlier [18]. The use of post therapy DCE-MRI in
cervical and endometrial cancer may be able to predict
which patients are at risk of early recurrence and therefore
super select patients suitable for exenterative surgery.
DCE-MRI
DCE-MRI is a non-invasive technique which can assess
tissue perfusion and oxygenation within the tumour
microenvironment [19]. Abnormalities in tumour micro-
vasculature and changes in perfusion can lead to hypoxia
which is considered a major factor in response of tumour
cells to radiation and in particular to radio-resistance
[1,20]. The ability to evaluate the extent of hypoxia may
be a useful predictive tool in identifying which patients
may benefit from additional or more aggressive therapies.
Direct measurement of oxygenation of the tumour
microenvironment is invasive, subject to sampling errors
and several techniques have not been fully validated
[21]. Imaging attention has been centred towards further
evaluating DCE-MRI as a predictive perfusion bio-
marker. The ability to use routine gadolinium based
contrast agents, most commercially available MRI scan-
ners and analysis software allows DCE-MRI to be widely
accessible. Moreover, the additional sequences are short
adding only 10 minutes of scan time which is well toler-
ated by patients.
DCE-MRI involves intravenous injection of standard
low-molecular weight paramagnetic intravascular con-
trast agents (typically gadolinium diethylene-triamine
penta-acetic acid), either as a fast bolus pump injection
or constant infusion. Serial image acquisitions are per-
formed every few seconds over a length of a few mi-
nutes, the exact protocols and the region of interest
depending on the tumour type being imaged.
The contrast agent reduces T1 longitudinal relaxation
time of blood which increases signal intensity (SI) en-
hancement, of vascular structures on T1 imaging. When
microcirculation of tumours is disrupted with angiogenesisand leaky capillary membranes, there is rapid accumula-
tion of contrast agents and subsequent enhancement of
tissues that is greater than that of similar normal tissue [2].
Semi-quantitative analysis
DCE indirectly evaluates distribution of contrast by meas-
uring tissue enhancement over time. The SI values are re-
corded before, during and after contrast administration
and a dynamic time-signal intensity (TSI) curve is gener-
ated using a fixed region of interest (ROI) within the organ
imaged (Figure 3).
The data that is commonly extracted from TSI curves
includes: time to onset of enhancement, relative signal
intensity (RSI), ratio of the maximum post-contrast SI to
the pre-contrast SI which is a measure of the degree of
enhancement, initial slope of the curve which is a meas-
ure of rate of enhancement and area under the curve
which represents overall enhancement [22].
Table 1 summaries the adnexal, cervical and endometrial
protocols used in the authors’ institution for both DCE
and DWI-MRI for semi-quantitative analysis (Table 1).
Quantitative analysis
Whilst clinical evaluation can be obtained from semi-
quantitative analysis, the data is not readily transferable
between scanners and measurements are not an accurate
assessment of the amount of contrast within the ROI
[19]. To overcome these shortfalls, quantitative analysis
is required. To perform quantitative analysis concentra-
tion of contrast is calculated within a ROI, deduced from
analysing properties of T1 relaxation times pre and post-
contrast. The National Cancer Institute has recom-
mended that quantitative measurements, such as Ktrans
(volume transfer constant between the plasma and the
extracellular extravascular space) and IAUGC (the initial
area under the gadolinium concentration–time curve],
should be used as primary endpoints for DCE-MRI stud-
ies [23]. However quantitative analysis requires extensive
support from dedicated MRI physicists and is labour in-
tensive. Consequently, this has led to mainly the use of
semi-quantitative DCE in clinical practice.
Figure 3 Enhancing endometrial carcinoma and type 3 malignant curve. a demonstrates the pre-contrast sagittal MRI through the uterus,
following contrast at a 72 second acquisition, there is enhancement of endometrial soft tissue (b), note that the tumour is less enhancing than
the adjacent myometrium and invasion by the tumour can clearly be seen. A region of interest (red circle) has been placed over the tumour and
a TCI created (c), this shows a type 3 malignant curve.
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Functional imaging with DWI is a non-invasive tech-
nique which generates tissue contrast from differences
in mobility of water molecules that occurs during an
MR pulse sequence [17]. Information regarding the in-
tegrity of cellular membranes and tissue cellularity can
be obtained [17,24]. Excellent contrast-to-noise ratio is
achieved based on differences in cellularity between tu-
mours, which usually return high signal, and normal
tissue, which usually returns low signal. The signal in-
tensity in DWI is derived from the intensity of MR pulse
sequence, represented by a b-value. B- values are in-
creased incrementally from low to high, typically ranging
from 0-1200s/mm2. As the B-values increase, this in-
creases the SI from tissues with high cellularity and
hence the conspicuity and detection of disease is in-
creased with suppression of bowel and background
tissue, however this is at the expense of signal-to-
noise ratio. High b-values between 800-1200s/mm2Table 1 Adnexal, cervical and endometrial MRI protocols for
Sequence Plane
DWI 2b-values (0,1200) Axial
DWI 3b-values (0,300,600) Axial (sagittal optional for endometrial ca
T1 fat sat Adnexal:Axial oblique
DCE 5 scans
36secs each
Scan time 3 mins Cervical and endometrial: Sagittalare preferred for imaging the female pelvis to elimin-
ate affects of T2 shine through from cysts, bladder
and bowel [24,25].
Quantitative assessment of the tumour microenviro-
ment can be derived from the apparent coefficient dif-
fusion (ADC) which is generated from combining serial
b-values [26]. Hence, DWI can be used to assess changes
in tumour cellularity over time in response to treatment
[16]. Acquisition of DWI and generation of ADC maps
is simple, fast, and does not require intravenous contrast
agents. ADC is a reproducible physical constant with ad-
vantageous features of a potential biomarker. ADC is ex-
quisitely sensitive to changes in the water environment,
therefore ADC values are affected by several factors
from the hardware (scanner type and field strength) to
the type of sequences used for example breath-hold, re-
spiratory triggered or free-breathing [27]. These factors
must be considered when interpreting changes in ADC
values to ensure they are not the result of measurementDWI and DCE-MRI at the authors institution
FOV Slice Gap Matrix NSA
400 5 1 112 × 256 3
ncer) 340 6 1 112 × 256 3
280 4 224 × 256 8
280 4 208 × 256 6
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Therefore in clinical practice and clinical trials the vari-
ability of ADC measurements should be minimised by
standardization of b values, standardising imaging proto-
cols and by consistent placement of serial ROI over time
which is essential to ensure reproducibility of data.
There is great interest in use of ADC as a biomarker
of early treatment response in several organs of the
body, particularly breast, rectal and intracranial neo-
plasms with growing evidence in gynaecological malig-
nancy, particularly cervical cancer [29,30].
Clinical application of Functional MRI
Cervical cancer
DCE-MRI as a predictor of radiotherapy response in cervical
cancer
Several studies have shown pre-treatment DCE-MRI pa-
rameters of high relative SI or peak enhancement are asso-
ciated with tumour regression and local tumour control
[19,21,31]. High perfusion before and during radiotherapy
suggests increased vascularity and high tumour oxygen-
ation, both associated with better response to treatment
and therefore better prognosis. Mayr et al demonstrated
an increase in tumour perfusion or relative SI early during
radiation therapy for cervical cancer suggesting improved
oxygenation of previously hypoxic cells making radiother-
apy more effective in these tumours. More recently, the
same group performed a longitudinal study evaluatingFigure 4 Cervical carcinoma showing restricted diffusion and enhanc
the cervix with parametrial invasion (a), the mass demonstrates restricted d
imaging (images c-f), indicating the tumour should respond well to treatmperfusion at three time points throughout treatment in 98
patients, they found that if initial pre-therapy perfusion
was low and subsequently changed to high perfusion early
in therapy, a favourable outcome was obtained, but per-
sistently low perfusion throughout treatment was associ-
ated with poor treatment response and poor prognosis
[21,31] (see Figures 4 and 5). The definition of low perfu-
sion varies between studies, Mayr et al analysed poorly per-
fused tumour subregions with voxel-by-voxel histogram
analysis and quantified the areas as lower 10th percent-
ile of the signal-intensity curve (SI10%) – this was the
value below which the lowest 10% of all tumour voxels fell
and which differentiated favourable from unfavourable
outcomes [31]. Yuh et al found that SI percentiles ranging
from SI5%-SI20% provided overall best prediction with the
single best predictor for primary tumour control was SI5%
at 2-2.5 weeks of therapy [32]. In the authors institution
qualitative assessment is also used to assess perfusion with
low perfusion taken to be tumour enhancement less than
normal cervical tissue and high perfusion taken to be
tumour enhancement greater than cervical tissue.
Table 2 summarises pre-therapy DCE-MRI studies in
cervical cancer and their key outcomes.
Post-therapy DCE-MRI in predicting recurrence
At completion of therapy, persistent enhancement at the
original cervical tumour site or in the post-surgical bed
likely represents residual disease associated with increasedement. Axial T2 image showing a mass in the right lateral aspect of
iffusion on high b-values (b) and marked enhancement on DCE
ent.
Figure 5 Poorly enhancing cervical tumour indicating poor response to treatment. Pre-treatment sagittal T2 MRI showing a tumour in the
posterior cervical lip (a), at the end of treatment there is recurrent disease (b) and 6 months later residual disease is present (c). The pre-treatment DCE
images are shown in figures d-g from pre-contrast to later contrast enhancement, minimal enhancement of the tumour is seen predicting the poor
outcome to treatment observed.
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DCE-MRI can be used as a predictive tool to pre-empt
or detect early residual disease and recurrences and
thereby select patients suitable for exenterative surgery






98 Semi-quantitative RSI throughout treatment
Zahra et al
2009 [19]
13 Semi-quantitative and quantitative. Assessed at
points, pre treatment, after 2 weeks of EBRT and
last week of EBRT
Mayr et al
1996 [21]
17 Semi-quantitative pre treatment and at 2 weeks
Yuh et al
2009 [32]




7 Semi-quantitative pre-treatment and at 2 wee
Yamashita et al
2000 [1]
36 Semi-quantitativeIn a small group of 10 patients with cervical cancer,
Boss et al used a cut-off value of 6 seconds on the end
of treatment DCE MRI to divide non-survivors and sur-
vivors. Early contrast enhancement of less than 6 seconds
was associated with poor survival, but delayed contrastey outcomes
Outcome
● Persistent low perfusion associated with poor prognosis
● Low perfusion which converts to high perfusion during
treatment associated with favourable response.
3 time
in the
● semi quantitative and quantitative DCE-MRI parameters correlate
significantly with tumour regression at the end of EBRT.
● Tumors with early peak SI, steeper slope for the TSI curve, and
higher values for CER, Ktrans, and kep had more significant
tumor regression and response to therapy
EBRT. ● High pre-treatment SI and steeper slope on TSI curve
correlated with lower incidence of local recurrence
● High perfusion early in therapy is a favourable prognostic
factor.
at 3 ● Tumor volume, mean SI, and SI% showed significant prediction
of the long-term clinical outcome
ks ● Mean and peak enhancement correlated with tumour
regression
● Tumours with homogenous contrast enhancement correlated
with good responders and poorly enhancing tumours with
poor responders
Figure 6 Recurrent disease. Recurrent mass at the left aspect of the vaginal vault after treatment for cervical cancer demonstrated on axial T2
images (a) and showing avid enhancement post contrast (b). DCE images (c-e) showing strong early contrast enhancement.
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proved survival [35]. However further research into the
ideal cut-off value in larger cohorts of patients is re-
quired to be of use in clinical practice.
DCE-MRI and tumour volume
Tumour size alone is an independent prognostic indica-
tor in cervical cancer, reflected in the FIGO staging. In
large cervical tumours it is thought areas of necrosis and
poor vascularity contribute to tumour hypoxia and low
contrast enhancement on DCE-MRI associated with
poorer response to therapy. This contrasts with small
highly vascular tumours which are more radiosensitive.
However Mayr et al demonstrated that there was a lack
of correlation between tumour volume and enhance-
ment in intermediate sized tumours (between 4-6 cm)
thought to reflect tumour heterogeneity [36]. The study
found combining tumour volumetry and DCE enhance-
ment variables help to refine the prediction of tumour
response in this subgroup.
ADC as a potential biomarker of tumour response
A number of authors have shown following chemoradia-
tion in cervical cancer the ADC value at the site of dis-
ease increases towards normal cervical ADC values, but
does not reach that of normal cervical tissue, reflecting afavourable response to treatment but not necessarily dif-
ferentiating post-treatment fibrosis from residual tumour
[4,37]. This is thought to be due to effects of anti-cancer
therapies causing tumour lysis, increased extracellular
space which allows an increase in mobility of water mol-
ecules and diffusion [4]. Limitations of the published
studies includes small numbers of patients analysed, the
lack of a histological gold standard and also in the study
by Chen et al, the ADC values were only evaluated in
the first 3 months of completion of therapy. Before DWI
can be used in routine monitoring of treatment, pre
treatment threshold values for ADC need to be deter-
mined. Long-term studies evaluating the change in ADC
values in different post-treatment stages are required.
Table 3 summarises pre and post treatment ADC values
in key studies in cervical cancer.
ADC as a biomarker of early response: mid-treatment
Harry et al demonstrated that there was a statistically
significant correlation between mid-treatment ADC
values and eventual MR and clinical response, there was
a 21% increase between the pre-treatment ADC and
mid-treatment values. No correlation was found between
pre-therapy, post-therapy ADC values or baseline
tumour size. The authors concluded in this small study
of 20 patients, that mid-treatment ADC values may be a
Table 3 Pre and post treatment ADC values in cervical cancer in key studies
Author No Pre-treatment ADC* Post treatment ADC Percentage change
Naganawa et al [37] 9 1.04 ± 0.17 1.48 ± 0.23 42%
Chen et al 2009 [4] 22 1.013 ± 0.094 1.436 ± 0.129 42%
Liu et al 2009 [38] 17 0.8 ± 0.08 1.08 ± 0.15 35%
*ADC [×10−3 mm2/s].
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tients with advanced cervical cancer [39].
Liu et al demonstrated two interesting findings in their
study; pre- treatment ADC was lower in patients who went
on to have a complete response (CR) compared to those in
the partial response (PR) group. Secondly, the CR group
mid-treatment ADC value increased rapidly and was
higher than in the PR group supporting the fact that ADC
values may predict those patients likely to be favourable re-
sponders [38]. Table 4 summaries ADC values at 3 time
points in CR and PR subgroups (See Table 4) Figures 7
and 8.
On review of the literature there is considerable over-
lap of the ADC values obtained pre, mid and post treat-
ment in good and bad responders. Therefore the
percentage change in ADC values at different time
points during treatment may be of more clinical value
than absolute ADC values. For example, in the work by
Liu et al, complete responders demonstrated a 56% in-
crease in pre and mid-treatment ADC values compared
to only 29% change in partial responders, whilst Harry
et al demonstrated a 21% increase between pre and mi-
treatment ADC values. Larger studies are required to
further establish clinical useful percentage parameters.
Association of ADC with survival and recurrence
In a follow up study by Somoye et al more recently, the
authors were able to show that patients who had higher
median mid-treatment ADC values had improved sur-
vival rates.
They found that survivors had a higher mid-treatment
ADC (1.55 × 10−3 mm2/s) than non-survivors (1.36 ×
10−3 mm2/s) which is a 14% difference. They found no evi-
dence of a difference between survivors and non-survivors
for pre-treatment or post-treatment ADC-values [15].
Ovarian cancer
DCE-MRI in recurrent ovarian carcinoma
There are a small number of studies which have compared
contrast enhanced MRI with second look laparotomiesTable 4 ADC values at 3 time points in CR and PR subgroups
Author No Baseline ADC Mid-treatment ADC
Liu et al 15 CR 0.81 ± 0.08 1.25 ± 0.10
PR 0.93 ± 0.09 1.20 ± 0.17and have found comparable results. In one retrospective
study of 68 patients with residual or recurrent tumour,
DCE-MRI had a sensitivity of 90% and specificity of 88%
compared with laparotomy (sensitivity 88%, specificity
100%) [40].
The authors concluded that serial Ca-125 in conjunc-
tion with MRI is more cost-effective than second look
laparotomy and is associated with less morbidity. There-
fore if a surgical approach is considered a pre-operative
MRI is a potentially useful tool to aid surgical planning.
There is limited published literature assessing DCE-
MRI in the response to treatment but one study by Sala
et al looked at multi-parametric MRI in 22 patients
treated for advanced ovarian disease and found that
there was no change in the DCE parameters in ovarian,
peritoneal and omental disease during treatment [41].
Contrast-enhanced MRI even without DCE is sensitive
in the detection of subcentimetre peritoneal and serosal
deposits due to the superior contrast resolution, particu-
larly on delayed 5 minute acquisitions [42]. A pitfall of
contrast enhanced MRI is that enhancement of the peri-
toneum and serosa is non-specific in the context of
post-treatment complications including sepsis, fistulae
and intra-operative chemotherapy [40,43].
DWI in ovarian and peritoneal disease
The sensitivity of contrast enhanced CT and MRI is
comparable in the detection of metastatic ovarian dis-
ease. Detection of peritoneal disease is difficult due to
poor contrast resolution between disease implants and
adjacent bowel and surrounding structures. Because
DWI demonstrates high contrast-to-noise ratio, detec-
tion of small volume subcentimetre disease is improved.
As mentioned earlier, the DWI images should always be
reviewed with the ADC maps and anatomical sequences
to exclude T2-shine through, for example fluid in simple
cysts will be high signal on T2 images and this can ‘shine
through’ onto the DWI and ADC maps, if the sequences
are not reviewed together then lesions may be inter-
preted as having restricted diffusion (which shouldin cervical cancer
S % change Post- treatment ADC % change
56% __________
29% 1.32 ± 0.23 42%
Figure 7 Cervical carcinoma showing marked restricted diffusion and good response to treatment. Pre treatment cervical cancer showing
a mass on sagittal and axial T2 images (a and b) which demonstrated marked restricted diffusion with high signal on b1200 images (c) and low
ADC (d). Post treatment, no residual mass or restricted diffusion is present consistent with a good response to treatment (e-h).
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structures which may appear bright on DWI imaging,
but are not disease related is important to avoid overcal-
ling disease, for example reactive lymph nodes and
bowel mucosa which have high cellularity [6]. When
combined with conventional anatomical MR sequences,
DWI improves accuracy to 84-88% on a per-lesion basis,
while MRI alone is 52-72% and DWI alone is 71-81%,
but this has yet to be correlated with a clinical impact
[44]. A study by Low et al demonstrated an increase in
detection of peritoneal deposits by 21% and 29% in 169
patients using single breath-hold DWI [45].
In one small study of 42 patients with recurrent ovar-
ian or peritoneal cancer the ADC values during chemo-
therapy were analyzed and the authors found that in
responders, the ADC values of lesions increased after
cycle 1 and 3 compared with non-responders where no
parameter changed significantly. Furthermore the pre-
treatment ADC were not predictive of response to treat-
ment. The authors concluded that quantitative DW-MRI
may aid early monitoring of treatment efficacy [46].
In the same study by Sala et al quoted earlier the au-
thors found that the baseline ADC of ovarian lesions,
peritoneal lesions and omental cake differed significantly
suggestive of biologic heterogeneity of disease. They also
found that post-treatment the ADC of ovarian lesions
increased significantly in responders where as there was
no change in ADC in non-responders. The authors con-
cluded that ADC values may be useful response markerswhereas no significant change was seen in DCE or spec-
troscopy parameters [41].
Endometrial carcinoma
DWI-MRI in predicting recurrence
There is limited literature evaluating DWI-MRI in predict-
ing recurrence in endometrial cancer. Multiple important
prognostic factors have been documented including age,
stage, histology, depth of myometrial invasion and lymph
node metastases however there are no biomarkers cur-
rently available to predict prognosis [6].
One study by Nakamura et al looked at 111 patients
who underwent surgery for endometrial cancer. The au-
thors found that there was a significant correlation be-
tween pre-treatment ADC values and FIGO stage, depth
of myometrial invasion, cervical involvement, lymph
node metastasis, peritoneal cytology and tumour size. In
particular lower ADC values were associated with grade
1 histological classification compared with grade 3, and
low ADC values were associated with disease free sur-
vival compared with patients with higher pre-treatment
ADC values. No association was found with overall sur-
vival, but the authors concluded low pre-operative ADC
could predict which patients have a low risk of recurrent
disease [47].
Future directions
A significant limitation of the current studies is the
small number of patients sampled and the lack of a
Figure 8 Residual disease post treatment. a demonstrates a pre-treatment large cervical mass on sagittal T2 imaging with marked restricted
diffusion (b and c). d demonstrates appearances mid-treatment with residual disease on T2 imaging and restricted diffusion (e, f). At the end of
treatment g-i demonstrates residual disease which has increased in size with corresponding increase in restricted diffusion.
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is desirable and recommended in guidelines published by
the National Institute of Cancer for DCE-MRI, this is
labour intensive requiring MRI physicist support. ADC as
a quantitative, reproducible predictive tool shows great
promise but also needs standardisation of b-values be-
tween institutions and further research into identifying
threshold values. Percentage change in ADC values at
various treatment points may serve as a better indicator of
response than absolute values. In cervical cancer long-
term studies evaluating differences in ADC values in the
post-therapy setting over a longer time period may help to
overcome the challenge of differentiating residual disease
from fibrosis. There is a lack of published data evaluating
functional imaging in both recurrent endometrial and
ovarian cancer. The role of whole body MRI and PET-
MRI are currently limited to the research setting but these
modalities may have added benefit to the assessment of
pelvic gynaecological malignancy due to the exquisite
combination of high resolution anatomical and functional
images. Further research into the correlation of early dis-
ease detection with long term survival and disease free
morbidity is required to assess the clinical utility of ad-
vanced functional imaging.
Conclusion
The majority of published data has evaluated functional
MRI and cervical cancer with promising results to date.
Some limited studies have shown added value of func-
tional MRI in recurrent endometrial and ovarian cancers.
Given that both DCE-MRI and DWI-MRI are non-
invasive, readily accessible and without ionising radiation,
there are advantages in being able use these techniques to
further individualise and benefit patient care.
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